Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plitidepsin for post-COVID-19 condition
2024-516378-31-00Phase 2Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Feb 2025
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome comparing Plitidepsin with Placebo (2 arms). Primary endpoint: PROMIS-29 T-score at Day 90. Started Feb 2025; status: completed.
02
Drugs
plitidepsin
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2024-516378-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516378-31-00.